Immuno-oncology – Endpoints News

Ticker	Current Price	Change	Graph
IBB	108.32	0.15 (0.14%)
XBI	87.99	0.13 (0.15%)

GlaxoSmithKline sets its sights on a quick leap into the big PD-1/L1 game — will anyone notice?

by John Carroll — on March 20, 2019 06:56 AM EDT
Updated: 04:49 PM

Roche stacks up Tecentriq nods, following up breast cancer approval with small cell lung cancer

by Natalie Grover — on March 19, 2019 06:04 AM EDT

Roche claims a first in breast cancer as Tecentriq/Abraxane combo nabs quick approval in frontline use

by Amber Tong — on March 11, 2019 07:31 AM EDT

Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure’s preclinical work on next-gen antibody

by John Carroll — on March 5, 2019 06:43 AM EDT

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

by Natalie Grover — on February 26, 2019 05:48 AM EDT

In the battle against kidney cancer, Merck’s keystone immunotherapy Keytruda edges in front

by Natalie Grover — on February 12, 2019 09:06 AM EDT
Updated: 09:13 AM

FDA promises speedy review on moving Merck’s Keytruda up as first-line head and neck cancer therapy

by Amber Tong — on February 11, 2019 10:01 AM EDT

AbbVie jumps into the frenzied race for a BCMA/CD3 bispecific targeting multiple myeloma. Teneobio who?

by John Carroll — on February 11, 2019 08:35 AM EDT
Updated: 11:15 AM

Canaan leaps into UK biotech by co-leading $14M Series A for immuno-oncology upstart Grey Wolf

by Natalie Grover — on February 11, 2019 01:00 AM EDT

Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors

by Natalie Grover — on February 8, 2019 09:17 AM EDT
Updated: 12:19 PM

Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer

by John Carroll — on February 8, 2019 08:43 AM EDT

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson

by Amber Tong — on January 16, 2019 09:42 AM EDT

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug

by Amber Tong — on January 16, 2019 07:14 AM EDT
Updated: 07:18 AM

Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer

by John Carroll — on January 14, 2019 08:18 AM EDT
Updated: January 15, 2019 03:01 PM

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

by John Carroll — on January 9, 2019 10:27 AM EDT
Updated: 10:29 AM

After blueprinting R&D hub, AbbVie dishes out $105M for CD39 pact with Tizona’s new CEO from Roche

by Amber Tong — on January 3, 2019 10:27 AM EDT

Cash-poor Agenus finds itself a generous partner in Gilead, shares surge

by Natalie Grover — on December 20, 2018 09:02 AM EDT
Updated: 09:41 AM

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment

by John Carroll — on December 20, 2018 04:45 AM EDT

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing

by John Carroll — on December 14, 2018 09:37 AM EDT

Targeting CD47? UCLA joins bandwagon, with gel to stem tumors from resurfacing

by Endpoints Staff — on December 11, 2018 07:35 AM EDT
Updated: 10:35 AM

Category: Immuno-oncology